Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity

Charles Lawrence Loprinzi, Richard R. Love, James A. Garrity, Matthew M. Ames

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Ocular toxicity is a common, but poorly understood, sequela from CMF chemotherapy. We investigated this toxicity in patients receiving CMF therapy. Detailed interviews in 210 patients revealed that new, unpleasant ocular symptoms developed in 42% of patients receiving CMF, in 39% of subjects receiving other regimens containing 5-fluorouracil (5-FU), and only in 18% of subjects receiving a variety of chemotherapy regimens not containing 5-FU. CMF-associated ocular symptoms usually consisted of mild to marked tearing, ocular pruritis, and/or burning. These toxicities usually began 11-17 days after starting a cycle of CMF and lasted for 10-15 days. 5-FU was detected in the tears of 12 tested patients within several minutes after intravenous 5-FU (peak concentrations as high as 60 μg/ml). 5-FU tear concentrations did not correlate with the presence or absence of ocular toxicity. There is no established antidote for this toxicity although some patients have reported subjective benefit from cryotherapy, applied around the period of 5-FU injections, or cromolyn sodium eye drops.

Original languageEnglish (US)
Pages (from-to)459-465
Number of pages7
JournalCancer Investigation
Volume8
Issue number5
DOIs
StatePublished - 1990

Fingerprint

Methotrexate
Fluorouracil
Cyclophosphamide
Tears
Drug Therapy
Cromolyn Sodium
Antidotes
Cryotherapy
Ophthalmic Solutions
Pruritus
Interviews
Injections

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity. / Loprinzi, Charles Lawrence; Love, Richard R.; Garrity, James A.; Ames, Matthew M.

In: Cancer Investigation, Vol. 8, No. 5, 1990, p. 459-465.

Research output: Contribution to journalArticle

Loprinzi, Charles Lawrence ; Love, Richard R. ; Garrity, James A. ; Ames, Matthew M. / Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity. In: Cancer Investigation. 1990 ; Vol. 8, No. 5. pp. 459-465.
@article{22d16d548b3d438088b1610d7e8092ef,
title = "Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity",
abstract = "Ocular toxicity is a common, but poorly understood, sequela from CMF chemotherapy. We investigated this toxicity in patients receiving CMF therapy. Detailed interviews in 210 patients revealed that new, unpleasant ocular symptoms developed in 42{\%} of patients receiving CMF, in 39{\%} of subjects receiving other regimens containing 5-fluorouracil (5-FU), and only in 18{\%} of subjects receiving a variety of chemotherapy regimens not containing 5-FU. CMF-associated ocular symptoms usually consisted of mild to marked tearing, ocular pruritis, and/or burning. These toxicities usually began 11-17 days after starting a cycle of CMF and lasted for 10-15 days. 5-FU was detected in the tears of 12 tested patients within several minutes after intravenous 5-FU (peak concentrations as high as 60 μg/ml). 5-FU tear concentrations did not correlate with the presence or absence of ocular toxicity. There is no established antidote for this toxicity although some patients have reported subjective benefit from cryotherapy, applied around the period of 5-FU injections, or cromolyn sodium eye drops.",
author = "Loprinzi, {Charles Lawrence} and Love, {Richard R.} and Garrity, {James A.} and Ames, {Matthew M.}",
year = "1990",
doi = "10.3109/07357909009012068",
language = "English (US)",
volume = "8",
pages = "459--465",
journal = "Cancer Investigation",
issn = "0735-7907",
publisher = "Informa Healthcare",
number = "5",

}

TY - JOUR

T1 - Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity

AU - Loprinzi, Charles Lawrence

AU - Love, Richard R.

AU - Garrity, James A.

AU - Ames, Matthew M.

PY - 1990

Y1 - 1990

N2 - Ocular toxicity is a common, but poorly understood, sequela from CMF chemotherapy. We investigated this toxicity in patients receiving CMF therapy. Detailed interviews in 210 patients revealed that new, unpleasant ocular symptoms developed in 42% of patients receiving CMF, in 39% of subjects receiving other regimens containing 5-fluorouracil (5-FU), and only in 18% of subjects receiving a variety of chemotherapy regimens not containing 5-FU. CMF-associated ocular symptoms usually consisted of mild to marked tearing, ocular pruritis, and/or burning. These toxicities usually began 11-17 days after starting a cycle of CMF and lasted for 10-15 days. 5-FU was detected in the tears of 12 tested patients within several minutes after intravenous 5-FU (peak concentrations as high as 60 μg/ml). 5-FU tear concentrations did not correlate with the presence or absence of ocular toxicity. There is no established antidote for this toxicity although some patients have reported subjective benefit from cryotherapy, applied around the period of 5-FU injections, or cromolyn sodium eye drops.

AB - Ocular toxicity is a common, but poorly understood, sequela from CMF chemotherapy. We investigated this toxicity in patients receiving CMF therapy. Detailed interviews in 210 patients revealed that new, unpleasant ocular symptoms developed in 42% of patients receiving CMF, in 39% of subjects receiving other regimens containing 5-fluorouracil (5-FU), and only in 18% of subjects receiving a variety of chemotherapy regimens not containing 5-FU. CMF-associated ocular symptoms usually consisted of mild to marked tearing, ocular pruritis, and/or burning. These toxicities usually began 11-17 days after starting a cycle of CMF and lasted for 10-15 days. 5-FU was detected in the tears of 12 tested patients within several minutes after intravenous 5-FU (peak concentrations as high as 60 μg/ml). 5-FU tear concentrations did not correlate with the presence or absence of ocular toxicity. There is no established antidote for this toxicity although some patients have reported subjective benefit from cryotherapy, applied around the period of 5-FU injections, or cromolyn sodium eye drops.

UR - http://www.scopus.com/inward/record.url?scp=0025672845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025672845&partnerID=8YFLogxK

U2 - 10.3109/07357909009012068

DO - 10.3109/07357909009012068

M3 - Article

C2 - 2124943

AN - SCOPUS:0025672845

VL - 8

SP - 459

EP - 465

JO - Cancer Investigation

JF - Cancer Investigation

SN - 0735-7907

IS - 5

ER -